title: Circulating clinical strains of human parainfluenza virus reveal viral entry requirements for in vivo infection.
abstract: Human parainfluenza viruses (HPIVs) cause widespread respiratory infections, with no vaccines or effective treatments. We show that the molecular determinants for HPIV3 growth in vitro are fundamentally different from those required in vivo and that these differences impact inhibitor susceptibility. HPIV infects its target cells by coordinated action of the hemagglutinin-neuraminidase receptor-binding protein (HN) and the fusion envelope glycoprotein (F), which together comprise the molecular fusion machinery; upon receptor engagement by HN, the prefusion F undergoes a structural transition, extending and inserting into the target cell membrane and then refolding into a postfusion structure that fuses the viral and cell membranes. Peptides derived from key regions of F can potently inhibit HPIV infection at the entry stage, by interfering with the structural transition of F. We show that clinically circulating viruses have fusion machinery that is more stable and less readily activated than viruses adapted to growth in culture. Fusion machinery that is advantageous for growth in human airway epithelia and in vivo confers susceptibility to peptide fusion inhibitors in the host lung tissue or animal, but the same fusion inhibitors have no effect on viruses whose fusion glycoproteins are suited for growth in vitro. We propose that for potential clinical efficacy, antivirals should be evaluated using clinical isolates in natural host tissue rather than lab strains of virus in cultured cells. The unique susceptibility of clinical strains in human tissues reflects viral inhibition in vivo.
  
  
  OBJECTIVE
  Acute respiratory infection is the leading cause of mortality in young children under 5 years of age, causing nearly 20% of childhood deaths worldwide each year. The paramyxoviruses, including human parainfluenza viruses (HPIVs), cause a large share of these illnesses. There are no vaccines or drugs for the HPIVs. Inhibiting entry of viruses into the human cell is a promising drug strategy that blocks the first step in infection. To develop antivirals that inhibit entry, it is critical to understand the first steps of infection. We found that clinical viruses isolated from patients have very different entry properties from those of the viruses generally studied in laboratories. The viral entry mechanism is less active and more sensitive to fusion inhibitory molecules. We propose that to interfere with viral infection, we test clinically circulating viruses in natural tissues, to develop antivirals against respiratory disease caused by HPIVs.
authors.affiliation: Departments of Pediatrics and of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA.
authors.forename: Samantha G
authors.initials: SG
authors.lastname: Palmer
authors.affiliation: Departments of Pediatrics and of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA.
authors.forename: Ilaria
authors.initials: I
authors.lastname: DeVito
authors.affiliation: Department of Pathology, Weill Medical College of Cornell University, New York, New York, USA.
authors.forename: Stephen G
authors.initials: SG
authors.lastname: Jenkins
authors.affiliation: Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, Ohio, USA.
authors.forename: Stefan
authors.initials: S
authors.lastname: Niewiesk
authors.affiliation: Departments of Pediatrics and of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA.
authors.forename: Matteo
authors.initials: M
authors.lastname: Porotto
authors.affiliation: Departments of Pediatrics and of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA anm2047@med.cornell.edu.
authors.forename: Anne
authors.initials: A
authors.lastname: Moscona
mesh_terms: D000818:Animals; D002478:Cells, Cultured; D005260:Female; D015707:HN Protein / Q000378:metabolism; D006801:Humans; D010224:Parainfluenza Virus 3, Human / Q000502:physiology*; D016205:Sigmodontinae; D014760:Viral Fusion Proteins / Q000378:metabolism; D053586:Virus Internalization
chemical_list: D015707:HN Protein; D014760:Viral Fusion Proteins; C072983:F protein, parainfluenza virus 3